Skip to main content
SpringerLink
Log in

Short-Term Effects of Tolvaptan in Tricuspid Insufficiency Combined with Left Heart Valve Replacement-Caused Volume-Overload Patients: Results of a Prospective Pilot Study

  • Original Research Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Objectives

Our objective was to explore the effects of tolvaptan as a new therapeutic approach in patients with right heart failure with tricuspid insufficiency (TI).

Methods

This prospective, multicenter, non-randomized controlled pilot study enrolled patients (N = 40) with TI from the Shanghai Chest Hospital and Shanghai Tongren Hospital who fulfilled inclusion criteria between March 2015 and June 2016. Participants were assigned to receive either tolvaptan combined with torasemide (n = 20) or torasemide monotherapy (n = 20; control group). The primary endpoints were changes in patient weight and in tricuspid annular plane systolic excursion (TAPSE) after 10 days of treatment. The secondary endpoints included net fluid balance and cardiac functions before and after medication from the first to the tenth day of treatment. Safety was evaluated by monitoring adverse and serious adverse events.

Results

TAPSE significantly increased in the tolvaptan group compared with the control group after 10 days of medication (P = 0.029). Daily weight losses in the tolvaptan group significantly increased as the time of treatment increased (time × group, P = 0.022). Recovery to New York Heart Association (NYHA) grade I occurred 4 days earlier in the tolvaptan group. In addition, the net fluid balance and median net fluid balance were significantly higher in the tolvaptan group. Eight adverse events and one serious adverse event were recorded in the tolvaptan group and 15 adverse events were recorded in the control group.

Conclusions

Our results indicate that tolvaptan might be a useful and safe drug to improve heart function in patients with right heart failure with TI after left heart valve replacement.

Clinical Trial Registration

ClinicalTrials.gov identifier no. NCT02644616.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Izumi C. Tricuspid regurgitation following left-sided valve surgery: echocardiographic evaluation and optimal timing of surgical treatment. J Echocardiogr. 2015;13(1):15–9. https://doi.org/10.1007/s12574-014-0236-y.

    Article  PubMed  Google Scholar 

  2. Vargas Abello LM, Klein AL, Marwick TH, Nowicki ER, Rajeswaran J, Puwanant S, et al. Understanding right ventricular dysfunction and functional tricuspid regurgitation accompanying mitral valve disease. J Thorac Cardiovasc Surg. 2013;145(5):1234.e5–1241.e5. https://doi.org/10.1016/j.jtcvs.2012.01.088.

    Article  Google Scholar 

  3. Chan KM, Zakkar M, Amirak E, Punjabi PP. Tricuspid valve disease: pathophysiology and optimal management. Prog Cardiovasc Dis. 2009;51(6):482–6. https://doi.org/10.1016/j.pcad.2008.08.009.

    Article  PubMed  Google Scholar 

  4. Wong RC, Abrahams Z, Hanna M, Pangrace J, Gonzalez-Stawinski G, Starling R, et al. Tricuspid regurgitation after cardiac transplantation: an old problem revisited. J Heart Lung Transplant. 2008;27(3):247–52. https://doi.org/10.1016/j.healun.2007.12.011.

    Article  PubMed  Google Scholar 

  5. Gargani L, Schmidt PH, Gheorghiade M. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion. Expert Rev Cardiovasc Ther. 2011;9(12):1505–13. https://doi.org/10.1586/erc.11.163.

    Article  CAS  PubMed  Google Scholar 

  6. Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O’Brien T, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011;17(12):973–81. https://doi.org/10.1016/j.cardfail.2011.08.005.

    Article  CAS  PubMed  Google Scholar 

  7. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist—pharmacology and clinical trials. Cardiovasc Drug Rev. 2007;25(1):1–13. https://doi.org/10.1111/j.1527-3466.2007.00001.x.

    Article  CAS  PubMed  Google Scholar 

  8. Payvar S, Orlandi C, Stough WG, Elkayam U, Ouyang J, Casscells SW, et al. Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia. Am J Cardiol. 2006;98(11):1485–8. https://doi.org/10.1016/j.amjcard.2006.06.051.

    Article  PubMed  Google Scholar 

  9. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31. https://doi.org/10.1001/jama.297.12.1319.

    Article  CAS  PubMed  Google Scholar 

  10. Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013;53(12):1277–85. https://doi.org/10.1002/jcph.197.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zulkifli Amin H, Suridanda Danny S. Tolvaptan: a novel diuretic in heart failure management. J Tehran Heart Center. 2016;11(1):1–5.

    Google Scholar 

  12. Ikeda Y, Inomata T, Iida Y, Nabeta T, Iwamoto M, Ishii S, et al. The vasopressin V2-receptor antagonist, tolvaptan, can not only induce aquaresis but also enhance natriuresis in heart failure patients refractory to loop diuretics. Eur Heart J. 2013;34(suppl_1):P3338-P. https://doi.org/10.1093/eurheartj/eht309.p3338.

    Article  Google Scholar 

  13. Rodriguez Y, Mesa J, Arguelles E, Carrillo RG. Tricuspid insufficiency after laser lead extraction. Pacing Clin Electrophysiol PACE. 2013;36(8):939–44. https://doi.org/10.1111/pace.12160.

    Article  PubMed  Google Scholar 

  14. Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation. 2005;112(9 Suppl):I453–7. https://doi.org/10.1161/CIRCULATIONAHA.104.524421.

    Article  PubMed  Google Scholar 

  15. Takano H, Hiramatsu M, Kida H, Uenoyama M, Horiguchi K, Yamauchi T, et al. Severe tricuspid regurgitation after mitral valve surgery: the risk factors and results of the aggressive application of prophylactic tricuspid valve repair. Surg Today. 2017;47(4):445–56. https://doi.org/10.1007/s00595-016-1395-4.

    Article  PubMed  Google Scholar 

  16. Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, et al. Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery. Heart. 2009;95(11):931–6. https://doi.org/10.1136/hrt.2008.152793.

    Article  CAS  PubMed  Google Scholar 

  17. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107(21):2690–6. https://doi.org/10.1161/01.cir.0000070422.41439.04.

    Article  CAS  PubMed  Google Scholar 

  18. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034–41. https://doi.org/10.1164/rccm.200604-547OC.

    Article  PubMed  Google Scholar 

  19. Niwa T, Waseda K, Mizuno T, Nakano Y, Mukai K, Wakabayashi H, et al. Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure. J Echocardiogr. 2017;15(3):118–26. https://doi.org/10.1007/s12574-017-0330-z.

    Article  PubMed  Google Scholar 

  20. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014;78(4):844–52.

    CAS  PubMed  Google Scholar 

  21. Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291(16):1963–71. https://doi.org/10.1001/jama.291.16.1963.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Fang Yuan and Zhangmin Wu contributed equally to this paper.

Authors and Affiliations

  1. Department of Cardiology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200336, China

    Fang Yuan, Zhangmin Wu, Li Jiang & Jun Zhou

  2. Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China

    Lei Xu & Hua Liu

  3. Department of Ultrasound, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, China

    Lan Ma

  4. Department of Emergency, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200336, China

    Zhenzhou Zhai & Junjie Zhang

Authors
  1. Fang Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhangmin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lan Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhenzhou Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junjie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Jiang.

Ethics declarations

Conflicts of interest

Fang Yuan, Zhangmin Wu, Li Jiang, Jun Zhou, Lei Xu, Hua Liu, Lan Ma, Zhenzhou Zhai, and Junjie Zhang have no conflicts of interest that might be relevant to the contents of this manuscript.

Availability of data and material

All data generated or analyzed during this study are included in this article.

Funding

This study was funded by the Acute Heart Failure Specialist (Grant number: 20162002).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuan, F., Wu, Z., Jiang, L. et al. Short-Term Effects of Tolvaptan in Tricuspid Insufficiency Combined with Left Heart Valve Replacement-Caused Volume-Overload Patients: Results of a Prospective Pilot Study. Am J Cardiovasc Drugs 19, 211–218 (2019). https://doi.org/10.1007/s40256-018-0304-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-018-0304-1

Search

Navigation